Merck & Co: Keytruda Headed for Extended Dominance in Cancer Market

Merck & Co. Inc. (NYSE:MRK) announced today that Keytrudaâ€”its cancer drugâ€”has been granted a breakthrough therapy designation by the Food and Drug Administration (FDA) for the treatment of relapsed or refractory classical Hodgkin lymphoma (cHL). The announcement marks the fourth breakthrough therapy designation for the first-ever anti-PD-1 therapy to be approved in the US.
http://www.bidnessetc.com/67407-merck-keytruda-headed-extended-dominance-cancer-market/

AUDIENCES

Caregivers
Friends and Family
General Public
Medical Profession
Patients
Survivors

SUBJECTS

Post Surgical

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2024 Esophageal Cancer Education Foundation- by domino